Complete Histologic Remission after Sunitinib Neoadjuvant Therapy in T3b Renal Cell Carcinoma

Robert, G.; Gabbay, G.; Bram, Raphaël; Wallerand, Hervé; Déminière, C.; Cornelis, F.; Bernhard, Jean-Christophe; Ravaud, Alain; Ballanger, P.

doi:10.1016/j.eururo.2008.12.036

Cited by 62 publications

(25 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[18][19][20][21][22] Although no objective criteria exist to reproducibly define surgical resectability, the situation in which a tumor is not resectable due to size or local invasion occurs, although infrequently. This scenario represents an ideal setting for preoperative therapy, to the extent that a given agent may yield tumor volume reduction.…”

Section: Discussionmentioning

confidence: 99%

Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma

Cowey

Amin

Pruthi

et al. 2010

JCO

183

View full text Add to dashboard Cite

A B S T R A C T PurposeThe multitargeted tyrosine kinase inhibitor sorafenib is used for the treatment of advanced-stage renal cell carcinoma. However, the safety and efficacy of this agent have yet to be evaluated in the preoperative period, where there may be potential advantages including tumor downstaging. This prospective trial evaluates the safety and feasibility of sorafenib in the preoperative setting. Patients and MethodsThirty patients with clinical stage II or higher renal masses, selected based on their candidacy for nephrectomy, underwent preoperative treatment with sorafenib. Toxicities, surgical complications, and tumor responses were monitored. ResultsOf the thirty patients enrolled, 17 patients had localized disease and 13 had metastatic disease. After a course of sorafenib therapy (median duration, 33 days), a decrease in primary tumor size (median, 9.6%) and radiographic evidence of loss of intratumoral enhancement, quantified using a methodology similar to Choi criteria (median, 13%), was also observed. According to Response Evaluation Criteria in Solid Tumors, of the 28 patients evaluable for response, two patients had a partial response and 26 had stable disease, with no patients progressing on therapy. Toxicities from sorafenib were similar to that expected with this class of medication. All patients were able to proceed with nephrectomy and no surgical complications related to sorafenib administration were observed. ConclusionThe administration of preoperative sorafenib therapy can impact the size and density of the primary tumor and appears safe and feasible. Further studies are required to determine if preoperative systemic therapy improves outcomes in patients undergoing nephrectomy for renal cell carcinoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma

Cowey

Amin

Pruthi

et al. 2010

JCO

183

View full text Add to dashboard Cite

show abstract

“…One of the primary concerns of neoadjuvant targeted therapy is the potential to make conditions worse for surgical resection because of bleeding complications or poor wound healing. Recent publications have reported interesting effects of sunitinib as neoadjuvant therapy [6,7]. Lauren reported that pre-surgical tyrosine kinase inhrbitor (TKI) use was associated with increased incidence and grade of intra-operative adhesions but was not associated with a significant increase in peri-operative complications or peri-operative bleeding [9].…”

Section: Discussionmentioning

confidence: 99%

“…Some recent publications have suggested promising results with neoadjuvant therapy, including partial remission of the primary tumor, vena cava thrombus, and lymph node metastases [2][3][4][5][6][7]. We present the case of a patient who underwent successful resection of T4 RCC after a neoadjuvant targeted therapy using sunitinib, and review the pertinent literature.…”

Section: Introductionmentioning

confidence: 99%

Successful Treatment of T4 Renal Cell Carcinoma After a Neoadjuvant Targeted Therapy Using Sunitinib: Report of a Case

Ueda

Noguchi²,

Suekane

et al. 2011

Kurume Med. J.

View full text Add to dashboard Cite

Summary:Since the introduction of targeted therapy, treatment of metastatic renal cell carcinoma (RCC) has undergone dramatic changes. Responses to targeted therapy within the primary tumor and metastatic lesions are novel findings not seen with immunotherapeutic-based strategies. We report here a case of T4 RCC in which cytoreductive nephrectomy became possible after a neoadjuvant targeted therapy using sunitinib. Our experience with the present case suggests that targeted therapy in the neoadjuvant setting may have a variety of potential applications. Further investigations should be encouraged.

show abstract

“…2). Тем не менее НАТ не всегда успешна у пациентов с опухолевым тромбозом в нижней полой вене [29][30][31][32][33][34][35].…”

Section: лекцияunclassified

“…У большинства па циентов (93 %) заре-гистрирована стабилизация заболевания по крите-Таблица 2. Эффективность таргетной терапии у больных ПКР с опухолевым тромбозом [18,22,[29][30][31][32][33][34][35] …”

Section: лекцияunclassified

Neoadjuvant targeted therapy in patients with renal cell carcinoma

Алексеев¹,

Нюшко²,

Калпинский³

2015

Onkourologiya

View full text Add to dashboard Cite

Complete Histologic Remission after Sunitinib Neoadjuvant Therapy in T3b Renal Cell Carcinoma

Cited by 62 publications

References 7 publications

Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma

Neoadjuvant Clinical Trial With Sorafenib for Patients With Stage II or Higher Renal Cell Carcinoma

Successful Treatment of T4 Renal Cell Carcinoma After a Neoadjuvant Targeted Therapy Using Sunitinib: Report of a Case

Neoadjuvant targeted therapy in patients with renal cell carcinoma

Contact Info

Product

Resources

About